ANT-GROUP
3.11.2022 04:21:38 CET | Business Wire | Press release
Ant Group today officially launched its Alipay+ D-store™ at the Singapore FinTech Festival 2022. Alipay+ D-store™ is a business digitalization solution designed to support the service industry, especially brick-and-mortar businesses to digitalize their operations to boost efficiency and productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221102006207/en/
(Photo: Business Wire)
An integrated one-stop solution which businesses can use to build digital stores across multiple digital platforms in a fast, scalable and cost-efficient way, Alipay+ D-store™ provides a suite of toolkits to digitalize merchants' payments, operations, services and marketing, unlocking new revenue opportunities and delivering better services to consumers.
Businesses could have digital stores on digital platforms in the form of mini programmes. Digital stores could also be developed as H5 pages and easily embedded in social media and online to reach consumers. Digital platforms currently partnering with Alipay+ D-store™ include Chope, Alipay, Touch 'n Go eWallet, AlipayHK, etc.
“We welcome more digital platforms to collaborate to accelerate the digitalization of the global service industry together,” Dr. Cherry Huang, Global Head of Alipay+ D-store™ said.
“Leveraging digital solutions is critical for the service industries to boost operational efficiency and adapt to the fast-changing market conditions. The Alipay+ D-store™ solution is developed with the goal to make it easier for brick-and-mortar businesses to go digital at scale, so that businesses can better serve and engage digital-savvy consumers by providing a seamless omni-channel experience,” she added.
Having identified the F&B industry a priority sector, Alipay+ D-store™ solution has been adopted by brands including fast food chain Burger King, Koufu, one of Singapore’s most established and largest operators and managers of food courts and coffee shops, and more than 2,000 local restaurants, cafes and eateries in Singapore, Malaysia, Hong Kong SAR, China and other markets.
At the Festival, Alipay+ D-store™ also unveiled its newest customer, Huggs Coffee, one of Singapore’s largest homegrown cafe chain brands specializing in coffee with over 20 outlets. Huggs will work with Alipay+ D-store™ to digitalize its outlets and operations efficacy, allowing customers to access seamless services through its digital store on Chope and other platforms in future.
Speaking in regard to the partnership, Lee Haoming, Managing Director of Huggs Coffee said: “Huggs is not only a business of F&B, to us, a good cup of coffee is a tool to create social connections. That is why creating a unique and elevated experience beyond the coffee itself is important to Huggs, and we believe digitalization plays an important role in enhancing the experience.”
“We are very excited to partner with Alipay+ D-store™ to transform the Huggs experience! It creates a more efficient operation flow to brew more smiles while reducing time to queue and pay, henceforth allowing our valued customers to spend more quality time on building connections with each other when visiting Huggs.”
To learn more about Alipay+ D-store™ at the Singapore FinTech Festival 2022, visit the Ant Group booth #2E01, or attend the product showcase “It’s A PLUS: How Alipay+ & Partners Build Digital Resilience For Businesses” scheduled at 11:20 a.m., 3 November in Hall 3.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, it strives to provide all consumers and small and micro businesses equal access to digital, financial, and other daily life services that are convenient, sustainable, and inclusive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom